Everest Medicines Announces New Drug Application Acceptance of NefeconĀ® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

SHANGHAI, Dec. 26, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for…